Q32 Bio Inc. - 8-K Filing
Q32 Bio reports positive Phase 2a trial results for bempikibart in alopecia areata with mean SALT score reduction of 35.3% and plans registration-directed trials by mid-2027. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $QTTB